

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 22 2005

In re Patent Application of Francis-Lang, *et al.*
Application No.: 10/528,032

Filed: March 16, 2005

For: RORS AS MODIFIERS OF THE P21
PATHWAY AND METHODS OF USE

Confirmation no.: 1012

Attorney Docket No.: EX03-068C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.


In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required for the submission of this IDS. However, if this belief is in error, the Commissioner is authorized to charge any required fees to deposit account no. 50-1108.

Respectfully submitted,

Dated: April 20, 2005


Laleh Shayesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234



App. No. 10/528,032
Docket No. EX03-068 S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Francis-Lang, *et al.*

Confirmation No.: 1012

Application No.: 10/528,032

Attorney Docket No.: EX03-068C-US

Filed: March 16, 2005

For: RORS AS MODIFIERS OF THE P21 PATHWAY AND METHODS OF USE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:

WO9306215, SALK INST FOR BIOLOGICAL STUDIES, 1993-04-01
WO0024757, TULARIK INC, 2000-05-04


The above-references have not been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the “Information Disclosure Statement by Applicant” filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: April 20, 2005

Laleh Shayesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number 10/528,032

Filing Date 03-16-2005

First Named Inventor Francis-Lang

Art Unit

Examiner Name

Attorney Docket Number EX03-068C-US


NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	1	Miki,N., et al. Homo sapiens RAR-related orphan receptor A (RORA), transcript variant 3, mRNA. Genbank GI:19743899		
	2	Miki,N., et al. Homo sapiens RAR-related orphan receptor A (RORA), transcript variant 2, mRNA. Genbank GI:19743900		
X	3	Miki,N., et al. Homo sapiens RAR-related orphan receptor A (RORA), transcript variant 1, mRNA. Genbank GI:19743902		
X	4	Giguere,V., et al. Human orphan hormone nuclear receptor RORalpha2 mRNA, complete cds. Genbank GI:451565		
X	5	Strausberg,R.L., et al. Homo sapiens RAR-related orphan receptor A, mRNA (cDNA clone MGC:12811 IMAGE:4121602), complete cds. Genbank GI:14250723		
X	6	Becker-Andre,M., et al. Human transcription factor RZR-alpha mRNA, complete cds. Genbank GI:348240		
X	7	Miki,N., et al. Homo sapiens RAR-related orphan receptor A (RORA), transcript variant 4, mRNA. Genbank GI:19743904		
X	8	Sumi,Y., et al. Homo sapiens RAR-related orphan receptor B (RORB), mRNA. Genbank GI:19743906		
X	9	Becker-Andre,M. H.sapiens mRNA for nuclear orphan receptor ROR-beta. Genbank GI:1619293		
X	10	Strausberg,R.L., et al. Homo sapiens RAR-related orphan receptor B, mRNA (cDNA clone IMAGE:6141868), partial cds. Genbank GI:30704550		
X	11	Winoto,A. et al. Homo sapiens RAR-related orphan receptor C (RORC), mRNA. Genbank GI:19743908		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	10/528,032
Filing Date	03-16-2005
First Named Inventor	Francis-Lang
Art Unit	
Examiner Name	

Attorney Docket Number

EX03-068C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X	12	Bahr,A., et al. Homo sapiens mRNA; cDNA DKFZp667A0710 (from clone DKFZp667A0710). Genbank GI:21739736	
X	13	Hirose,T., et al. Human orphan receptor ROR gamma mRNA, complete cds. Genbank GI:758419	
X	14	Strausberg,R.L., et al. Homo sapiens RAR-related orphan receptor C, transcript variant 1, mRNA (cDNA clone MGC:34470 IMAGE:5186655), complete cds. Genbank GI:21594879	
X	15	Ota,T., et al. Homo sapiens cDNA FLJ40675 fis, clone THYMU2021714, highly similar to NUCLEAR RECEPTOR ROR-GAMMA. Genbank GI:21757912	
X	16	Miki,N., et al. RAR-related orphan receptor A isoform b [Homo sapiens]. Genbank GI:19743901	
X	17	Sumi,Y., et al. RAR-related orphan receptor B [Homo sapiens]. Genbank GI:19743907	
X	18	Wang,H., et al. RAR-related orphan receptor C isoform a [Homo sapiens]. Genbank GI:19743909	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.